Baliforsen - Ionis Pharmaceuticals

Drug Profile

Baliforsen - Ionis Pharmaceuticals

Alternative Names: BIIB 065; IONIS-DMPK-2.5Rx; ISIS 598769; ISIS DMPKRx; ISIS-DMPK-2.5Rx

Latest Information Update: 15 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myotonic dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myotonic dystrophy

Most Recent Events

  • 01 Aug 2016 Ionis Pharmaceuticals completes a phase-I/II clinical trial in Myotonic dystrophy in USA (SC) (NCT02312011)
  • 15 Jun 2016 Phase-II clinical trials in Myotonic dystrophy in USA (SC) (Ionis Pharmaceuticals pipeline, June 2016)
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top